Lucite tombstone recognizing the acquisition of GeneTx BioTherapeutics. GeneTx has focused on a therapy for Angelman syndrome, a rare neurogenic disease. (22ALJ280)
Lucite tombstone recognizing the acquisition of GeneTx BioTherapeutics. GeneTx has focused on a therapy for Angelman syndrome, a rare neurogenic disease. (22ALJ280)
Custom Lucite marking the acquisition of GeneTx, an Illinois-based developer of treatments for rare genetic disorders.